Dexamethasone Base Pharma Grade API is manufactured as a crystalline glucocorticoid powder with the molecular formula C22H29FO5 and a molecular weight of 392.46 g/mol. The product code DEX-B-PH identifies the anhydrous free base, not the water-soluble sodium phosphate ester or the acetate derivative. Release is controlled under the current USP Dexamethasone monograph and Ph. Eur. 0388, with residual solvent testing aligned to ICH Q3C and elemental impurity control aligned to ICH Q3D Option 1 for oral and parenteral finished-product categories. The micronized grade has a laser-diffraction D90 of 10 µm–15 µm; the standard unmilled grade retains not more than 5% on a 40 mesh sieve. The compendial release profile includes an assay of 97.0%–103.0% on the dried basis, loss on drying not more than 0.5%, residue on ignition not more than 0.2%, and total related substances not more than 0.50%. The product is intended for tablets, capsules, granules, oral and injectable suspension formulations, where the free base is required rather than a water-soluble derivative.

What Release Specifications and Analytical Methods Are Applied to Dexamethasone Base API?

Release testing is configured to separate the free base from synthetic intermediates, degradation products, and residual process solvents. The following controls are reported on a certificate of analysis.

The HPLC system used for assay and related substances employs a 150 mm × 4.6 mm column packed with 5 µm octadecylsilane, with detection at 254 nm. System-suitability criteria include a dexamethasone peak tailing factor not more than 1.5, theoretical plates not less than 5000, and replicate injection RSD not more than 1.0%. The quantitation limit for unspecified impurities is established at 0.05% area. Residual solvent analysis is performed by headspace gas chromatography with flame ionization detection under USP <467>. Elemental impurities are measured by inductively coupled plasma mass spectrometry under USP <233>; the control strategy uses the ICH Q3D Option 1 table for oral and injectable routes because the same API stream may be directed to either finish. Particulate matter for injectable applications is controlled at the finished suspension stage by USP <788>, not at the API release stage.

The free base is practically insoluble in water; the aqueous solubility is below 0.1 mg/mL at 25 °C, while solubility in ethanol and acetone is higher. Dissolution is therefore the rate-limiting variable for immediate-release oral products. Micronization increases specific surface area and shortens the time to 80% drug release in compendial dissolution media. Jet milling is performed with nitrogen at gas pressures of 6 bar–8 bar, with classifier speed adjusted to maintain the D90 target. Nitrogen milling limits oxidative degradation and reduces electrostatic charge. The micronized powder is cohesive and does not flow reliably from an 800 L intermediate bulk container without a pre-blend. On high-volume tablet lines, the API is first co-sieved with an equal mass of spray-dried lactose monohydrate through a 0.5 mm screen; the pre-blend is then mixed in a bin blender at 10 rpm–15 rpm for 15 min before final blending.

Powder X-ray diffraction is used to confirm that the micronization step does not induce detectable amorphous content. Differential scanning calorimetry is performed on retention samples to confirm the crystalline melting endotherm; the compendial melting range is 250 °C–253 °C when determined by a standardized capillary method. Loss on drying is controlled because residual moisture influences compactibility and long-term related-substance formation.

When Dexamethasone Base Is Formulated Into Tablets, Capsules, and Granules

Direct compression at drug loads of 0.5%–2.0% w/w requires geometric dilution. A three-stage blending sequence is used on production batches. The first stage mixes the API with an equal mass of lactose monohydrate in a 100 L bin blender at 25 rpm for 10 min. The second stage adds the remaining diluent and half of the disintegrant and mixes for 10 min. The third stage adds the remaining disintegrant and colloidal silicon dioxide and mixes for 5 min. Magnesium stearate is then added at 0.5%–1.0% w/w and mixed for 3 min–5 min to prevent over-lubrication. Blend uniformity is verified according to ASTM E2810-19; low-dose blends are expected to meet 90%–110% label claim with an RSD not more than 5%. Tablet compression is performed on a rotary press with precompression force of 2 kN–5 kN to control capping because the micronized API can reduce compactibility at high speed.

Wet granulation is used when higher drug loads and improved flow for capsule filling are required. A binder solution of hydroxypropyl cellulose at 5% w/w solids is added to the drug-laden dry mix in a high-shear granulator with a main impeller tip speed of 4 m/s–8 m/s. Water addition is stopped by a power-consumption endpoint; over-wetting produces dense granules that fail disintegration. The wet mass is passed through a 1.0 mm screen and dried in a fluid-bed dryer with inlet air at 50 °C–60 °C until granule moisture is below 2.0%. Dried granules are milled through a 0.8 mm screen. The resulting granulation is charged to a dosator-type capsule machine; the higher bulk density of the granulation reduces weight variation relative to direct fill of micronized powder.

Capsule strengths from 0.25 mg to 4 mg per unit are produced from a granulated or roller-compacted pre-blend of API, lactose monohydrate, and croscarmellose sodium. Roller compaction is performed at a roll pressure of 30 kN–60 kN and a roll speed of 4 rpm–8 rpm; the ribbons are milled through a 1.0 mm screen. The API is not combined with strong oxidizing agents or strongly alkaline excipients because the α-hydroxy ketone side chain is susceptible to oxidative and base-catalyzed degradation. Magnesium stearate is kept at or below 1.0% w/w to avoid reducing tablet hardness and dissolution.

For injectable suspension manufacture, the micronized free base is dispersed in an aqueous vehicle containing a suspending agent and a wetting agent. The free base is not suitable for solution injection; the sodium phosphate ester is used for IV or IM solution formulations because of high water solubility. Aqueous suspensions of dexamethasone base are typically processed aseptically because terminal steam sterilization may cause particle aggregation and syringeability failure. Where terminal sterilization is evaluated, the suspension is autoclaved at 121 °C for 15 min; however, published data for this specific formulation configuration are limited, and stability under thermal cycling must be confirmed. Syringeability is measured through a 21 G needle under a force of not more than 25 N using a texture analyzer. The finished suspension is tested for particulate matter by light obscuration according to USP <788> and for bacterial endotoxins according to USP <85>, with a common limit of 0.5 EU/mg for sterile-suspension applications.

Differences from Dexamethasone Sodium Phosphate and Acetate Ester Forms

The free base is the reference form for label claims. A 1.3 mg quantity of dexamethasone sodium phosphate contains approximately 1 mg of dexamethasone base; a 1.1 mg quantity of dexamethasone acetate contains approximately 1 mg of base. The phosphate ester is freely soluble and is selected for parenteral solution and oral liquid formulations. The acetate form has a more hydrophobic surface and is used in topical and ophthalmic suspensions where slower dissolution is desired. The base form is not directly interchangeable with the sodium phosphate ester in solid dosage manufacturing because the difference in molecular weight, particle density, and dissolution rate requires reformulation. Betamethasone base, the 16β-methyl stereoisomer, is covered by a separate monograph and is not considered equivalent under ICH Q6A decision trees without a separate drug-substance specification.

The non-sterile API is double-bag-packed in low-density polyethylene inside a sealed aluminum foil laminate drum with desiccant. Storage is controlled at 15 °C–25 °C with relative humidity below 60%. Long-term and accelerated stability studies are conducted according to ICH Q1A; the retest period is assigned from statistical analysis of assay, related substances, and moisture content. The API is incompatible with strong oxidizing agents and with strongly alkaline excipients. For injectable-grade applications, the manufacturer applies additional bioburden and bacterial endotoxin limits, because the base form is intended for aseptic suspension preparation rather than routine terminal steam sterilization. The material is supplied with a certificate of analysis that includes residual solvents by USP <467>, elemental impurities by USP <233>, and particle-size data by USP <429> for the micronized grade.